Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXONASDAQ:CLNNNASDAQ:HILSNASDAQ:TCDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$0.49+4.0%$0.52$0.41▼$10.97$25.94M1.21979,410 shs363,921 shsCLNNClene$3.12+13.9%$2.85$2.28▼$9.20$28.03M0.4682,092 shs189,676 shsHILSHillstream BioPharma$1.45-1.9%$1.34$0.19▼$2.65$25.56M3.081.39 million shs22,725 shsTCDATricida$0.13$0.09▼$13.85$6.01M0.2217.62 million shs31.13 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology0.00%+4.77%-8.84%-52.83%-95.43%CLNNClene0.00%+31.65%+4.70%-27.94%-52.58%HILSHillstream BioPharma0.00%+6.97%-16.06%+1.55%-69.40%TCDATricida0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALXOALX Oncology3.7582 of 5 stars4.42.00.00.02.73.31.3CLNNClene2.5485 of 5 stars3.63.00.00.01.42.50.6HILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.71Moderate Buy$3.30579.29% UpsideCLNNClene 3.17Buy$40.001,182.05% UpsideHILSHillstream BioPharma 0.00N/AN/AN/ATCDATricida 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TCDA, ALXO, HILS, and CLNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025ALXOALX OncologyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/9/2025ALXOALX OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.005/8/2025CLNNCleneBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $33.005/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/23/2025CLNNCleneJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.004/8/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.004/8/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/24/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/24/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/12/2025CLNNCleneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/12/2025CLNNCleneD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$3.81 per shareN/ACLNNClene$350K80.08N/AN/A$2.09 per share1.49HILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/ATCDATricidaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$160.80M-$2.47N/AN/AN/AN/A-93.02%-70.67%8/7/2025 (Estimated)CLNNClene-$49.50M-$4.04N/AN/AN/A-8,556.77%-1,106.30%-85.11%8/6/2025 (Estimated)HILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/ATCDATricida-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/ALatest TCDA, ALXO, HILS, and CLNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ALXOALX Oncology-$0.47-$0.58-$0.11-$0.58N/AN/A5/7/2025Q1 2025CLNNClene-$1.10-$0.50+$0.60-$0.09$0.07 million$0.08 million3/24/2025Q4 2024CLNNClene-$1.21-$1.67-$0.46-$1.67$0.13 million$0.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.074.824.82CLNNCleneN/A0.830.82HILSHillstream BioPharmaN/A3.013.01TCDATricidaN/A4.874.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%CLNNClene23.28%HILSHillstream BioPharma13.36%TCDATricidaN/AInsider OwnershipCompanyInsider OwnershipALXOALX Oncology33.40%CLNNClene35.30%HILSHillstream BioPharma30.24%TCDATricida35.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology4053.40 million35.13 millionOptionableCLNNClene1008.98 million6.24 millionOptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableTCDATricida5755.67 million35.85 millionNot OptionableTCDA, ALXO, HILS, and CLNN HeadlinesRecent News About These CompaniesTricida CEO to Pay $14 Million in Class Suit Over Drug ProgressMarch 4, 2025 | news.bloomberglaw.comPatrick G Enright's Net WorthMay 5, 2024 | benzinga.comSierraConstellation Partners Receives Industry Recognition for Work with TricidaFebruary 6, 2024 | finance.yahoo.comTricida Inc (TCDAQ)January 13, 2024 | es.investing.comEmerging Therapies in the Treatment of Clostridium difficile-Associated DiseaseMay 30, 2023 | medscape.comVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo FinanceApril 18, 2023 | news.google.comMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital JournalApril 17, 2023 | news.google.comReal-time PCR as a Diagnostic Tool for Bacterial DiseasesApril 12, 2023 | medscape.comChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital JournalApril 10, 2023 | news.google.comChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital JournalApril 6, 2023 | news.google.comTricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360March 24, 2023 | news.google.comAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo FinanceMarch 14, 2023 | news.google.comAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo FinanceMarch 14, 2023 | news.google.comTricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360March 6, 2023 | news.google.comTroubled Adamis To Merge With Private DMK, Focus On ... - ScripMarch 1, 2023 | news.google.comRelease Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360February 27, 2023 | news.google.comRenibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360February 21, 2023 | news.google.comSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comFebruary 18, 2023 | news.google.comTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comFebruary 18, 2023 | news.google.comTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo FinanceFebruary 14, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCDA, ALXO, HILS, and CLNN Company DescriptionsALX Oncology NASDAQ:ALXO$0.49 +0.02 (+3.98%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.49 +0.00 (+0.04%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Clene NASDAQ:CLNN$3.12 +0.38 (+13.87%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$3.19 +0.07 (+2.24%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Hillstream BioPharma NASDAQ:HILS$1.45 -0.03 (-1.88%) As of 05/30/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.Tricida NASDAQ:TCDATricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
